Analysts have slightly revised their price target for Healthpeak Properties downward from $21.38 to $21.31. This change reflects minor updates to discount rate and valuation assumptions.
What's in the News
- Healthpeak Properties, Inc. (NYSE:DOC) was dropped from the FTSE All-World Index (USD) (Key Developments)
- From April 1, 2025 to July 24, 2025, the company repurchased 3,944,683 shares, representing 0.56 percent for $71.87 million. With this, Healthpeak completed the repurchase of 5,091,156 shares, or 0.73 percent, for $94.17 million under the buyback announced on July 25, 2024 (Key Developments)
- Healthpeak Properties updated earnings guidance for full year 2025. Expected diluted earnings per common share were lowered from $0.30 to $0.36 to $0.25 to $0.31 (Key Developments)
Valuation Changes
- Fair Value Estimate: decreased slightly from $21.38 to $21.31.
- Discount Rate: edged down from 8.17% to 8.14%.
- Revenue Growth Projection: remained stable at approximately 3.05%.
- Net Profit Margin: held steady at around 6.42%.
- Future P/E Ratio: declined modestly from 93.78x to 93.35x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.